Shire's intrathecal ERT misses in MPS II trial

Shire plc (LSE:SHP; NASDAQ:SHPG) said intrathecal idursulfase (SHP609; formerly HGT-2310) missed the primary endpoint in the Phase II/III HGT-HIT-094 trial to

Read the full 211 word article

User Sign In